Mirikizumab

米吉珠单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameMirikizumab
Drug Alias Nameミリキズマブ（遺伝子組換え）OmvohOMVOH安妥来安妥来利 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-23 subunit p19 inhibitors
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Global Approved IndicationsCrohn DiseaseColitis, Ulcerative
Approved Indications in ChinaCrohn DiseaseColitis, Ulcerative
Original Approved Country/TerritoryJapan
Original Approved Date2023/03/27
Country/TerritoryCzechiaBelgiumCanada +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly Japan KkEli Lilly And CompanyEli Lilly Nederland BV +[5] 
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseInflammatory Bowel DiseasesColitis, Ulcerative
Inactive IndicationsPlaque psoriasisPsoriasis

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG